These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3309195)

  • 1. CAF in metastatic breast cancer: standard therapy or another effective regimen?
    Hayes DF; Henderson IC
    J Clin Oncol; 1987 Oct; 5(10):1497-9. PubMed ID: 3309195
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
    Vogel CL; Raney M; Carpenter J
    Cancer Treat Rep; 1987 Dec; 71(12):1271-3. PubMed ID: 3690536
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
    Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
    J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
    Taguchi T; Sakai K; Terasawa T; Wada H
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials referral resource. Adjuvant therapy of breast cancer.
    Cheson BD
    Oncology (Williston Park); 1989 Jun; 3(6):70-1, 74-5, 78. PubMed ID: 2534915
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
    Vogel CL; Smalley RV; Raney M; Krauss S; Carpenter J; Velez-Garcia E; Fishkin E; Raab S; Moore MR; Stagg M
    J Clin Oncol; 1984 Jun; 2(6):643-51. PubMed ID: 6374057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
    Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
    J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
    Costanza ME; Weiss RB; Henderson IC; Norton L; Berry DA; Cirrincione C; Winer E; Wood WC; Frei E; McIntyre OR; Schilsky RL
    J Clin Oncol; 1999 May; 17(5):1397-406. PubMed ID: 10334524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Goodyear M
    J Clin Oncol; 1986 Mar; 4(3):442-4. PubMed ID: 3512787
    [No Abstract]   [Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
    Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
    BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternating versus sequential therapy in advanced breast cancer.
    Romero A; Rabinovich MG; Pérez JE; Macchiavelli M; Leone BA; Strauss E; Goldar D; Alvarez LA; Vallejo C
    Medicina (B Aires); 1987; 47(3):243-8. PubMed ID: 3326994
    [No Abstract]   [Full Text] [Related]  

  • 16. Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984).
    Jones SE; Brooks RJ; Takasugi BJ; Garewal HS; Giordano GF; Ketchel SJ; Jackson R; Heusinkveld RS; Kemmer SR; Moon TE
    Recent Results Cancer Res; 1984; 96():133-40. PubMed ID: 6396766
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of locally advanced cancer of the breast].
    Lluch A; Pascual A; Cervantes A; Antón A; Martínez Agulló A; Aviñó J; Alberola V; García-Conde J
    Med Clin (Barc); 1987 May; 89(1):7-10. PubMed ID: 3613742
    [No Abstract]   [Full Text] [Related]  

  • 18. Stimulation of human breast cancer in vivo. Experimental findings and clinical results.
    Baldini E; Gardin G; Naso C; Pronzato P; Rosso R; Rubagotti A; Monzeglio C; Brema F; Pastorino G; Amadori D
    Ann N Y Acad Sci; 1993 Nov; 698():418-22. PubMed ID: 8279781
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Cummings FJ; Gelman R; Horton J
    J Clin Oncol; 1985 Jul; 3(7):932-40. PubMed ID: 3894587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.